Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab‐refractory follicular lymphoma patients in the GADOLIN phase III study

AIMS: Rituximab is standard care in a number of lymphoma subtypes, including follicular lymphoma (FL), although many patients are resistant to rituximab, or develop resistance with repeated treatment, and a high proportion relapse. Obinutuzumab is a novel anti‐CD20 monoclonal antibody with improved...

Descripción completa

Detalles Bibliográficos
Autores principales: Gibiansky, Ekaterina, Gibiansky, Leonid, Buchheit, Vincent, Frey, Nicolas, Brewster, Michael, Fingerle‐Rowson, Günter, Jamois, Candice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710522/
https://www.ncbi.nlm.nih.gov/pubmed/31050355
http://dx.doi.org/10.1111/bcp.13974

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710522/
https://www.ncbi.nlm.nih.gov/pubmed/31050355
http://dx.doi.org/10.1111/bcp.13974

Ejemplares similares